source
- FDA releases draft PDUFA VIII commitment letter outlining goals and enhancements for 2028-2032The FDA on Thursday issued a proposed commitment letter for the upcoming PDUFA VIII cycle, which will cover fiscal years 2028 through 2032. The letter sets out the agency's performance targets for…
- Epilepsy drug from Ovid and Takeda receives fresh start under Perceptive-backed ventureAfter about 26 months since two Phase 3 trials failed, the epilepsy treatment candidate originally developed by Ovid Therapeutics and Takeda has been removed from their pipelines. Investment firm…